Condition: Excessive Hairiness · Vascular Lesion · Pigmented Lesions · Sponsor: Eurofeedback
The first IPL device obtained United States Food and Drug Administration (FDA) clearance in 1995 for treatment of lower extremity telangiectasias. Since then, its favorable cost and versatility in contrast to many singlespectrum lasers, has led to its rapid proliferation and use in a number of different clinical settings. As described in the literature, ANTHÉLIA medical device is intended to treat skin disorders: * Excessive Hairiness (Hirsutism, Hypertrichosis...) * Vascular lesions (Rosacea….) * Pigmented lesions (Lentigo et melasma) * Acne vulgaris
This description comes directly from the study's public registry record.
Laurent Zawadil · 01 60 86 31 10 · s.qualite@eurofeedback.com
Always discuss trial participation with your own doctor first.
| CH Auxerre | Auxerre, France | Recruiting |
| HIACT Brest | Brest, France | Recruiting |
| Centre TrialAzur | Nice, France | Recruiting |
| CH Périgueux | Périgueux, France | Not Yet Recruiting |
| CHU POitiers | Poitiers, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06655129